Core Viewpoint - Shanghai Kinetic Medical Co., Ltd. reported a 14.75% increase in revenue for the first half of 2025 compared to the same period in 2024, driven by growth in its vertebroplasty business and trade operations [6][22]. Company Overview and Financial Indicators - The company, listed as ST Kinetic with stock code 300326, operates primarily in the orthopedic implant medical device sector, focusing on the production, research, and sales of spinal minimally invasive products and orthopedic trauma implants [5][6]. - The total assets at the end of the reporting period were approximately CNY 3.35 billion, showing no significant change from the previous year [6]. Business Operations - The company specializes in vertebroplasty systems used for treating osteoporotic vertebral compression fractures, including percutaneous vertebroplasty (PVP) and percutaneous balloon kyphoplasty (PKP) systems [7][8]. - The company has established a joint venture with TECRES S.P.A. to develop and produce bone cement products, enhancing its product line in the orthopedic sector [9][19]. Financial Performance - Revenue for the reporting period was CNY 546.1 million, up from CNY 475.9 million in the previous year, with a corresponding increase in net profit attributable to shareholders of CNY 33.77 million, a 35.47% rise [6][22]. - Operating costs increased by 15.68% to CNY 269.83 million, primarily due to higher sales volume [22]. - The company reported a net cash flow from operating activities of CNY 65.62 million, reflecting a 38.68% increase compared to the previous year [22]. Strategic Developments - The company is focusing on optimizing its business model and resource allocation, particularly in response to the implementation of centralized procurement policies in the orthopedic sector [14][20]. - Recent acquisitions, including that of Elliquence, LLC, are aimed at expanding the company's product offerings and market reach in the orthopedic device field [11][18]. Market Position and Competitive Advantage - The company holds a leading market share in the vertebroplasty segment in China, benefiting from a strong brand reputation and established relationships with hospitals and distributors [20]. - Continuous investment in R&D and quality management has positioned the company favorably within the industry, allowing it to maintain a competitive edge [21].

Core Viewpoint - Shanghai Kelly Medical Technology Co., Ltd. reported a significant increase in revenue and net profit for the first half of 2025, indicating strong operational performance and growth potential in the medical technology sector [1][2]. Financial Performance - The company's operating income for the reporting period reached approximately 546.1 million yuan, representing a 14.75% increase compared to 475.9 million yuan in the same period last year [1]. - Net profit attributable to shareholders was approximately 43.8 million yuan, reflecting a 44.88% increase from 30.2 million yuan year-on-year [1]. - The net profit after deducting non-recurring gains and losses was about 45.1 million yuan, up 38.68% from 32.5 million yuan in the previous year [1]. - Basic earnings per share were reported at 0.0422 yuan, a decrease of 44.79% compared to 0.0611 yuan from the previous year [1]. Financial Position - Total assets at the end of the reporting period were approximately 3.35 billion yuan, showing a slight increase from 3.35 billion yuan at the end of the previous year [2]. - The net assets attributable to shareholders were approximately 2.77 billion yuan, up 1.68% from 2.72 billion yuan [2]. Shareholder Information - The top ten shareholders include various domestic investment companies, with the largest shareholder holding 6.99% of the shares [2][4]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [5].

Group 1 - The supervisory board of Shanghai Kelly Tai Medical Technology Co., Ltd. held its 22nd meeting and confirmed that the procedures for preparing and reviewing the 2025 semi-annual report comply with legal and regulatory requirements, ensuring the report accurately reflects the company's actual situation without any false statements or omissions [1][2] - The board approved a proposal for daily related transactions with associated companies, estimating a total amount not exceeding 30.55 million yuan (excluding tax) for 2025, compared to an actual transaction amount of 28.77 million yuan in 2024 [1][2] - The company reported an excess of 3.24 million yuan in daily related transactions for 2024, with specific excesses in service categories and sales to related parties [1][2] Group 2 - The management is authorized to conduct daily transactions within the approved amount, and any excess will require re-evaluation by the board or shareholders according to the Shenzhen Stock Exchange regulations [2] - The announcement regarding the recognition of excess related transactions for 2024 and the estimated transactions for 2025 is available on the designated information disclosure website [2] - The supervisory board's resolution document is available for review [2]

Group 1 - The company, Shanghai Kellytech Medical Technology Co., Ltd., has released its semi-annual report for 2025 on August 25, 2025 [1] - The report is available on the designated information disclosure website of the China Securities Regulatory Commission [1] - The board of directors ensures the authenticity, accuracy, and completeness of the disclosed information, with no false records, misleading statements, or significant omissions [1]

Core Viewpoint - The company has announced the recognition of excess related party transactions for the year 2024 and the expected related party transactions for the year 2025, with a total amount not exceeding 30.55 million yuan (excluding tax) for 2025 [1][2]. Summary by Sections 1. Basic Information on Related Party Transactions - The company expects to engage in related party transactions totaling no more than 30.55 million yuan for 2025, which includes sales, purchases, property leasing, and consulting services [1]. - The expected amount for related party transactions in 2024 was 43.30 million yuan, with an actual occurrence of 43.64 million yuan, resulting in an excess of 3.24 million yuan [1][2]. 2. Approval Process - The board of directors approved the recognition of excess related party transactions for 2024 and the expected transactions for 2025 with unanimous votes [2][18]. - The management is authorized to conduct daily transactions within the specified amount, and any excess will require further board or shareholder approval [2][18]. 3. Expected Related Party Transaction Categories and Amounts - The expected categories for 2025 include: - Rental of properties from Shanghai Ligetai: 3.80 million yuan - Rental of properties from Ligetai Equipment: 2.80 million yuan - Rental of properties from Shanghai Yijutai: 1.60 million yuan - Sales of goods to Shanghai Ligetai: 1.00 million yuan - Sales of goods to Tianjin Kangernuo: 0.50 million yuan - Consulting services from Shanghai Yueling: 1.00 million yuan - Total expected transactions amount to 30.55 million yuan [1][3][4]. 4. Previous Year’s Related Party Transactions - The actual occurrence of related party transactions for 2024 was 43.64 million yuan, with significant categories including: - Rental from Shanghai Ligetai: 3.67 million yuan - Rental from Ligetai Equipment: 2.56 million yuan - Purchases from Shanghai Yijutai: 6.43 million yuan - Total actual transactions were 28.77 million yuan [4][5]. 5. Related Party Information - Shanghai Ligetai has a registered capital of 65.50 million yuan and reported total assets of 468.78 million yuan as of December 31, 2024 [6][7]. - Ligetai Equipment has a registered capital of 6.88 million yuan and reported total assets of 47.21 million yuan as of December 31, 2024 [8]. - Shanghai Yijutai has a registered capital of 40 million yuan and reported total assets of 25.98 million yuan as of December 31, 2024 [9]. 6. Impact and Purpose of Related Party Transactions - The related party transactions are necessary for the company's normal production and operations, conducted on fair and voluntary terms, and do not harm the interests of the company or its shareholders [17][18]. - The transactions are expected to support the company's stable development and will not affect its independence [17][18].

Core Viewpoint - Shanghai Kelly Medical Technology Co., Ltd. is facing risk warnings due to an audit report from Zhonghua Accounting Firm indicating an inability to express an opinion on the company's internal controls for the 2024 financial year [1][2]. Group 1: Risk Warnings - The company’s stock trading has been subjected to other risk warnings as per the Shenzhen Stock Exchange's rules due to the audit report [1]. - The company is at risk of being subject to delisting warnings if the internal control audit report remains unaddressed [1]. Group 2: Measures Taken - The board of directors is taking the audit report seriously and has implemented measures to mitigate the issues raised [2]. - The company has revised its authority and established stricter review standards, along with conducting specialized training on related party transactions [2]. - The company is focusing on key investment projects, monitoring industry conditions, cash flow, debt structure, and compliance to avoid investment risks [2]. Group 3: Compliance and Reporting - The company encourages employees and stakeholders to report any internal violations or fraud to reduce the chances of misconduct [3]. - During the warning period, the company is required to disclose progress updates at least once a month until the situation is resolved [3].

上海凯利泰医疗科技股份有限公司 第五届监事会第二十二次会议决议公告 证券代码：300326 证券简称：凯利泰 公告编号：2025-087 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 4、会议由周志强先生主持，公司董事会秘书列席本次会议。 5、本次会议的召集、召开符合《中华人民共和国公司法》和《上海凯利泰 医疗科技股份有限公司章程》的规定。 二、监事会会议审议情况 1、审议通过了《关于公司 2025 年半年度报告的议案》 经审核，监事会认为：董事会编制和审核公司 2025 年半年度报告的程序符 合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公 司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 1 表决结果：本议案以 2 票同意、0 票反对、0 票弃权获得通过。 1、上海凯利泰医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 19 日以电话及邮件方式向公司各监事发出关于召开第五届监事会第二十二次会 议的通知。 2、公司于 2025 年 8 月 23 日 10 时在公司会议室以现场结合通讯方 ...

证券代码：300326 证券简称：凯利泰 公告编号：2025-086 表决结果：本议案以 7 票同意、0 票反对、0 票弃权、0 票回避获得通过。 《2025 年半年度报告》和《2025 年半年度报告摘要》详见中国证监会指定 的创业板信息披露网站，《2025 年半年度报告》披露的提示性公告同时刊登于《证 券时报》。 2、审议通过了《关于追认 2024 年度日常关联交易超额部分及预计 2025 年 上海凯利泰医疗科技股份有限公司 第六届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海凯利泰医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 19 日 以邮件方式向公司各董事发出关于召开第六届董事会第十次会议的通知，并于 2025 年 8 月 24 日上午 10 时在公司会议室以现场结合通讯方式召开。本次董事 会会议应出席的董事 7 名，实际出席会议的董事 7 名，其中惠一微、WEN CHEN （陈文）、金诗强、朱丁敏、刘学文、狄朝平以通讯表决方式出席会议。会议由 董事长王冲先生主持，公司全部高级管 ...

上海凯利泰医疗科技股份有限公司 2025 年半年度报告 上海凯利泰医疗科技股份有限公司 2025 年半年度报告全文 股票代码：300326 股票简称：ST 凯利 披露日期：二〇二五年八月二十六日 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 上海凯利泰医疗科技股份有限公司 1 公司负责人王冲、主管会计工作负责人李元平及会计机构负责人（会计 主管人员）李元平声明：保证本半年度报告中财务报告的真实、准确、完整。 二○二五年半年度报告 备查文件目录 （一）载有公司法定代表人、主管会计工作负责人、公司会计机构负责人（会计主管人员）签名并盖章的财务报表； 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告涉及的未来计划、发展战略等前瞻性描述不构成公司对投 资者的实质承诺，敬请投资者注意投资风险。公司在本报告"第三节、管理 层讨论与分析-十、公司面临的风险和应对措施"部分，详细描述了公司经营 中可能存在的风险及应对措施，敬请投资者关注相关内容。 公司计划不派发现金红利，不送 ...

证券代码：300326 证券简称：凯利泰 公告编号：2025-085 上海凯利泰医疗科技股份有限公司 2025年半年度报告披露的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司 2025 年半年度报告已于 2025 年 8 月 25 日在中国证监会指定的创业板信息披露网站上披露，请投资者注意查阅。 特此公告。 上海凯利泰医疗科技股份有限公司董事会 二〇二五年八月二十五日 1 ...